Moreover, IFN-β-engineered BM-MSCs can selectively home to locations of primary and metastatic pancreatic cancers, regulating TME and reducing the growth of pancreatic cancer [96]. This evidence concerns the gene IFNB1 and pancreatic neoplasm.